The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot study of liposomal irinotecan plus 5-FU/ LV combined with paricalcitol in patients with advanced pancreatic cancer which progressed on gemcitabine-based therapy.
 
Patrick Grierson
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Pancreatic Cancer
 
Rama Suresh
No Relationships to Disclose
 
Benjamin R. Tan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck Serono (Inst); Roche/Genentech (Inst); Sillajen (Inst); tyrogenex (Inst)
 
Katrina Sophia Pedersen
Consulting or Advisory Role - Array BioPharma; Bayer; Pfizer
Speakers' Bureau - Clinical Care Options
Research Funding - Abbvie (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Ipsen (Inst); Merck (Inst); Natera (Inst); Nouscom (Inst); Novartis (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Array BioPharma; BeiGene; Nouscom
 
Manik A. Amin
No Relationships to Disclose
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Vedanta Biosciences
 
Nikolaos Trikalinos
Research Funding - Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst)
 
Jingxia Liu
No Relationships to Disclose
 
Kian-Huat Lim
Honoraria - Jacobio
Research Funding - Aclaris Therapeutics
 
Andrea wang-gillam
Employment - Jacobio
Stock and Other Ownership Interests - Jacobio
Consulting or Advisory Role - AstraZeneca; Bayer; Inxmed; Merck
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Gossamer Bio (Inst); Hutchison MediPharma (Inst); Lilly (Inst); Merck (Inst); pfizer (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Verastem (Inst); Xcovery (Inst)